Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-Carboxamido Derivatives of Adenosine-5‘-N-ethyluronamide as A1 and A3 Adenosine Receptor Agonists
- 26 July 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (17) , 3174-3185
- https://doi.org/10.1021/jm980147p
Abstract
A new series of 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-β-d-ribofuranuronamide-bearing N-arylureas or N-arylcarboxamido groups at the purine 6 position and N-arylureas combined with halogens or alkynyl chains at the 2 position have been synthesized and tested for affinity at A1 and A2A adenosine receptors in rat brain membranes and at cloned rat A3 receptors expressed in CHO cells. The derivatives contained the 5‘ substituent found in the potent, nonselective agonist 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-β-d-ribofuranuronamide (NECA). While the carboxamido derivatives (9 − 13) showed affinity for A1 receptors, the urea derivatives (30 − 45) showed different degrees of affinity and selectivity for the A3 adenosine receptor subtype. In particular the derivative bearing a p-sulfonamidophenyl-urea at the 6 position, 31 showed a high affinity (Ki = 9 nM) and selectivity for the A3 receptors compared to that of the reference compound 1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-β-d-ribofuranuronamide (IB-MECA). Furthermore, the importance of the stereochemistry in the interaction of these ligands at the rat A3 adenosine receptors has been evaluated by introducing a chiral chain at the 6 position. The introduction of halogens or alkynyl chains at the purine 2 position of selected ureas did not give the expected enhancement of potency at A2A and/or A3 receptors but rather showed a dramatic reduction of A2A affinity, resulting in compounds with good A2A/A3 selectivity. For example, the 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)-6-(4-methoxyphenylurea) derivative 61 showed the capability to bind simultaneously to A1 and A3 receptor subtypes, excluding the A2A receptor. Compound 31 was shown to be an agonist, 9-fold more potent than NECA, at A3 receptors in rat RBL-2H3 mast cell membranes through stimulation of binding of [35S]GTP-γ-S.Keywords
This publication has 57 references indexed in Scilit:
- Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's diseaseTrends in Pharmacological Sciences, 1997
- Interactions of Flavonoids and Other Phytochemicals with Adenosine ReceptorsJournal of Medicinal Chemistry, 1996
- Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c] pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists.Bioorganic & Medicinal Chemistry Letters, 1994
- Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functionsTrends in Pharmacological Sciences, 1994
- Selective A1-Antagonists for Treatment of Cognitive DeficitsNucleosides and Nucleotides, 1991
- RDC8 codes for an adenosine A2 receptor with physiological constitutive activityBiochemical and Biophysical Research Communications, 1990
- Iodine-125-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptorsJournal of Medicinal Chemistry, 1988
- N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activityJournal of Medicinal Chemistry, 1987
- N6-Substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptorsJournal of Medicinal Chemistry, 1986
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973